1 week Ago By ABMN Staff
Shares of Tandem Diabetes Care, Inc. ( NASDAQ:TNDM – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the stock, Marketbeat.com reports.
Three equities research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $53.81.
Several research firms have commented on TNDM. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a report on Monday, December 2nd.
Robert W. Baird reduced their price objective on Tandem Diabetes Care from $39.00 to $37.
00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Barclays increased their target price on Tandem Diabetes Care from $58.00 to $60.
00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Citigroup reduced their price target on shares of Tandem Diabetes Care from $57.00 to $50.
00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, The Goldman Sachs Group began coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.
00 price objective for the company. Read Our Latest Research Report on Tandem Diabetes Care Tandem Diabetes Care Stock Performance Tandem Diabetes Care ( NASDAQ:TNDM – Get Free Report ) last released its earnings results on Wednesday, November 6th. The medical device company reported ($0.
35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08.
The firm had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million.
Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%.
The company’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.
38) earnings per share. Equities research analysts forecast that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.
Insiders Place Their Bets In other news, Director Kim D. Blickenstaff sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.
00, for a total transaction of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares of the company’s stock, valued at approximately $5,855,700.
The trade was a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link .
2.20% of the stock is owned by insiders. Institutional Investors Weigh In On Tandem Diabetes Care A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock.
JPMorgan Chase & Co. increased its position in shares of Tandem Diabetes Care by 134.6% during the third quarter.
JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock worth $8,379,000 after acquiring an additional 113,355 shares during the period. Franklin Resources Inc.
increased its holdings in Tandem Diabetes Care by 95.6% during the 3rd quarter. Franklin Resources Inc.
now owns 26,785 shares of the medical device company’s stock worth $1,136,000 after purchasing an additional 13,088 shares during the period. McIlrath & Eck LLC bought a new stake in Tandem Diabetes Care during the 3rd quarter valued at $52,000. Coldstream Capital Management Inc.
lifted its holdings in shares of Tandem Diabetes Care by 14.0% in the 3rd quarter. Coldstream Capital Management Inc.
now owns 6,212 shares of the medical device company’s stock worth $263,000 after buying an additional 762 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Tandem Diabetes Care by 1.2% during the 3rd quarter.
Geode Capital Management LLC now owns 1,525,816 shares of the medical device company’s stock worth $64,722,000 after buying an additional 18,187 shares in the last quarter. Tandem Diabetes Care Company Profile ( Get Free Report Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Recommended Stories Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter ..
